Events & Publications

December 10, 2023

Enhancing Antibody Language Models with Structural Information

Alchemab publication and NeurIPS Machine Learning in Structural Biology workshop

Learn More

December 10, 2023

Becoming Fluent in Proteins

Source: Cell Systems (November 2023)

Learn More

December 10, 2023

Building Representation Learning Models for Antibody Comprehension

Source: Cold Spring Harbour Perspectives in Biology (November 2023)

Learn More

December 7, 2023

Alchemab presents at Neuroscience 2023, the Society of Neuroscience annual meeting, held 11-15 November 2023

Michelle Sidor and Iosif Pediaditakis presented the following posters: 'Human-derived CD33 antibody ATLX-1088, a potent stimulator of microglial pharmacology' and 'Netrin-1 and neurodegenerative diseases: Unraveling Therapeutic Avenues'

Learn More

September 25, 2023

The Pharmaphorum Podcast

Listen to our CEO, Young Kwon discuss Alchemab's innovative platform and its novel approach to drug discovery on the pharmaphorum podcast.

Learn More

Alchemab Therapeutics CEO to Present at Wells Fargo 2023 Healthcare Conference

Learn More

September 5, 2023

Young at the Wells Fargo 2023 Healthcare Conference

Listen to CEO Young Kwon chat with Wells Fargo analyst Derek Archila at the Wells Fargo 2023 Healthcare Conference. Live webcast scheduled for Sep 7, 2023 at 4:30 pm ET.

Learn More

August 23, 2023

The Optimum Perspectives Podcast

Our CEO Young Kwon was delighted to speak with Richard Staines of the Optimum  Perspectives Podcast on how Alchemab is revolutionizing antibody drug discovery with a novel alternative to the classic "choose a target" approach.

Learn More

Q&A With Alchemab CEO Young Kwon in Drug Target Review

Learn More

July 17, 2023

Alchemab profiled in Drug Target Review

Alchemab was delighted to be featured in Drug Target Review in a profile by Izzy Wood. In the article, Izzy and Olivia Cavlan, our Chief Corporate Development and Strategy Officer, discuss the untapped potential of AI in drug target discovery and how Alchemab’s platform aims to identify common antibodies in resilient individuals and uncover the antigens that contribute to their disease-fighting abilities.

Learn More

June 21, 2023

Alchemab unveils Alzheimer’s candidate ATLX-1088 targeting CD33 at the Antibody Industrial Symposium 2023

Alchemab's Sandrine Legg, Director of Phenotypic Screening presented data on a potential first-in-class disease-modifying therapeutic for Alzheimer's disease at the Antibody Industrial Symposium in Tours, France on 22 June 2023.

Learn More

Alchemab unveils Alzheimer’s candidate ATLX-1088 targeting CD33 at the Antibody Industrial Symposium 2023

Learn More

May 5, 2023

Alchemab presents new data at CHDI Huntington’s Disease Therapeutics Conference 2023

Alchemab’s Donna Finch, Head of Translational and Clinical Science, presented data on a potential first-in-class disease modifying therapeutic for Huntington’s Disease at the annual CHDI Huntington’s Disease Therapeutics Conference in Dubrovnik, Croatia, on the 26 April 2023.

Learn More

May 5, 2023

Alchemab presents new data at CHDI Huntington’s Disease Therapeutics Conference 2023

See the attached presentation to learn more.

Learn More

Alchemab Therapeutics to present data profiling a novel antibody to Huntingtin Exon 1 at the CHDI Annual Huntington’s Disease Therapeutics Conference

Learn More

Alchemab Therapeutics and Medicines Discovery Catapult awarded £1.7 million grant from Innovate UKto accelerate development of disease-modifying therapy for Huntington’s Disease

Learn More

December 13, 2022

The Chain Podcast

Learn More

Nature Biotechnology’s academic spinouts 2021

Learn More

14th November 2022

Jane talks at PEGS 2022

Watch Jane's talks at PEGS 2022

Learn More

Young Kwon and Alchemab profiled in In Vivo

Learn More

Nature Biotechnology – Alchemab Therapeutics – Cracking the secrets of protective auto-immunity by Michael Eisenstein, 12 September 2022

Learn More

Alchemab Appoints Young T. Kwon as Chief Executive Officer

Learn More

AntiBERTa, an Antibody-Specific
Machine Learning Model with Multiple Applications

Learn More

04/05/2022

Jane talks at Genomics England Research Summit

Watch our CSO Jane Osbourn give a talk at the Genomics England Research Summit presenting our incredible work to date!

Learn More

4th May 2022

PEGS-2022-thumb

PEGS Boston 2022 – Parallel Discovery of Therapeutic Antibodies and Novel Targets Using Antibody Repertoires of Resilient Individuals

Watch Jorge Dias, Alchemab Principal Scientist and early member of the team, talk at PEGS Boston on ‘Parallel Discovery of Therapeutic Antibodies and Novel Targets Using Antibody Repertoires of Resilient Individuals’

Learn More

4th May 2022

Mining-the-immune-system-for-protective-antibodies-GEL-thumb

Genomics England Research Summit – Mining the immune system for protective antibodies

Learn more about B cell immune repertoires from Jane Osbourn, Alchemab CSO & co-founder, presenting at the Genomics England Research Summit

Learn More

24th March 2022

GTC 2022

Catch a replay of Alchemab’s Jin Leem presenting at Nvidia’s GTC 2022 on deciphering the language of antibodies

Learn More

Alchemab Selected to Access NVIDIA Cambridge-1 Supercomputer to Advance Machine Learning Enabled Antibody Discovery

Learn More

Alchemab Extends Partnership with Medicines Discovery Catapult

Learn More

Alchemab Therapeutics Appoints Young T. Kwon, PhD as Chief Financial and Operating Officer

Learn More

Alchemab Therapeutics Appoints Douglas A. Treco, PhD as Chief Executive Officer

Learn More

Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses

Learn More

Alchemab wins Best Emerging Biotech Start-Up at OBN Awards

Learn More

Alchemab to collaborate with AstraZeneca to use Alchemab’s drug discovery platform for prostate cancer study

Learn More

Alchemab raises £60 million ($82 million) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics

Learn More

Alchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease

Learn More

Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures

Learn More

Casting a spell: The Killer50 Magic Circle is unveiled

Learn More

Cambridge companies help develop Covid antibody cocktail

Learn More

Novel COVID-19 Antibody Therapy Candidates Identified by Leading UK Biotech Consortium

Learn More

UK-based Alchemab partners with Amii to accelerate the development of novel therapeutics to cure disease

Learn More

OBN Awards – Announcement of 2020 Finalists

Learn More

Agile start-ups partner with academics to find COVID-19 solutions

Learn More

Illumina unveils first Cambridge cohort for global genomics accelerator

Learn More

Illumina Accelerator Welcomes First Global Cohort of Genomics Startups

Learn More

Alchemab: One for the future and another first for Cambridge

Learn More

Deep sequencing of B cell receptor repertoires from COVID-19 patients reveals strong convergent immune signatures

Learn More

How the U.K. healthcare sector is leveraging its strengths to beat COVID-19

Learn More